Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$172.13 USD

172.13
5,803,034

+0.77 (0.45%)

Updated Jun 20, 2024 04:00 PM ET

After-Market: $172.38 +0.25 (0.15%) 5:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

    Gilead to Fly High with Kite Pharma Acquisition for $11.9B

    by Zacks Equity Research

    Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

      The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

        Roche's Gazyva Gets Priority Review for Follicular Lymphoma

        by Zacks Equity Research

        Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

          Biogen's Humira Biosimilar Imraldi Gets Approval in EU

          by Zacks Equity Research

          Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.

            Roche (RHHBY) Hemophilia A Drug Granted Priority Review

            by Zacks Equity Research

            Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

              AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

              by Zacks Equity Research

              AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

                Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

                by Zacks Equity Research

                Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

                  Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

                  by Zacks Equity Research

                  Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data

                    by Arpita Dutt

                    Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.

                      Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                      by Zacks Equity Research

                      Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

                        Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat

                        by Zacks Equity Research

                        Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote

                          by Arpita Dutt

                          Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.

                            Arpita Dutt headshot

                            Key FDA Events to Watch Out for in Aug 2017

                            by Arpita Dutt

                            Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                              AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

                              by Zacks Equity Research

                              AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

                                Arpita Dutt headshot

                                4 Drug Stocks in Focus this World Hepatitis Day

                                by Arpita Dutt

                                Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

                                  AbbVie (ABBV) Tops Q2 Earnings and Revenue

                                  by Zacks Equity Research

                                  AbbVie's (ABBV) second-quarter 2017 earnings surpassed estimates with revenue marginally beating the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure

                                    Jeffrey Hymen headshot

                                    Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV

                                    by Jeffrey Hymen

                                    The Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.

                                      Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

                                      by Zacks Equity Research

                                      Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

                                        Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

                                        by Zacks Equity Research

                                        Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

                                          Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

                                          by Zacks Equity Research

                                          Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

                                            Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

                                            by Zacks Equity Research

                                            Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                                              Sweta Killa headshot

                                              Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

                                              by Sweta Killa

                                              Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

                                                AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

                                                by Zacks Equity Research

                                                AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

                                                  Is Gilead (GILD) Poised for a Beat This Earnings Season?

                                                  by Zacks Equity Research

                                                  Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.